Cancer BiologybioRxivPreprint
PU.1 inhibition sensitizes stem-monocytic AML to BCL2 blockade
William M. Yashar, Itallia V. Pacentine, Akram Taherinasab…·Theodore P. Braun
This study identifies stem-monocytic AML as a distinct subtype resistant to venetoclax and shows that PU.1 inhibition synergizes with BCL2 blockade to enhance therapeutic response.